Posted by Michael Wonder on 03 Apr 2023
Nucala (mepolizumab) is now listed on the PBS for Australians with chronic rhinosinusitis with nasal polyps
3 April 2023 - Nucala is the first biologic treatment to be PBS-subsidised for the treatment of severe chronic rhinosinusitis with nasal polyps.
GSK Australia welcomes the announcement that Nucala (mepolizumab), will be subsidised by the Pharmaceutical Benefits Scheme from 1 April 2023 as an add-on treatment for adult patients (18 years and above) with chronic rhinosinusitis with nasal polyps that is severe, eosinophilic and recurrent post-surgery.
